www.neuropsychopharmacology.org

Singular Location and Signaling Profile of Adenosine A_{2A} -Cannabinoid CB_1 Receptor Heteromers in the Dorsal Striatum

Estefanía Moreno^{1,2}, Anna Chiarlone^{1,3,4}, Mireia Medrano^{1,2}, Mar Puigdellívol⁵, Lucka Bibic⁵, Lesley A Howell^{5,6}, Eva Resel^{1,3,4}, Nagore Puente^{7,8}, María J Casarejos⁴, Juan Perucho⁴, Joaquín Botta⁵, Nuria Suelves^{1,9}, Francisco Ciruela¹⁰, Silvia Ginés^{1,9}, Ismael Galve-Roperh^{1,3,4}, Vicent Casadó^{1,2}, Pedro Grandes^{7,8}, Beat Lutz¹¹, Krisztina Monory¹¹, Enric I Canela^{1,2}, Carmen Lluís^{*,1,2}, Peter J McCormick^{*,1,2,5,12} and Manuel Guzmán^{*,1,3,4}

¹Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain; ²Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain; ³Instituto Universitario de Investigación Neuroquímica and Department of Biochemistry and Molecular Biology I, Complutense University, Madrid, Spain; ⁴Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; ⁵School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, UK; ⁶School of Biological and Chemical Sciences, Queen Mary, University of London, London, UK; ⁷Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain; ⁸Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain; ⁹Biomedical Science Department, School of Medicine; Institut d'Investigacions Biomèdiques August Pi i Sunyer, and Neuroscience Institute, Barcelona University, Barcelona, Spain; ¹⁰Pharmacology Unit, Department of Pathology and Experimental Therapeutics, IDIBELL, and Neuroscience Institute, Barcelona University, Barcelona, Spain; ¹¹Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; ¹²Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK

The dorsal striatum is a key node for many neurobiological processes such as motor activity, cognitive functions, and affective processes. The proper functioning of striatal neurons relies critically on metabotropic receptors. Specifically, the main adenosine and endocannabinoid receptors present in the striatum, ie, adenosine A_{2A} receptor ($A_{2A}R$) and cannabinoid CB₁ receptor (CB₁R), are of pivotal importance in the control of neuronal excitability. Facilitatory and inhibitory functional interactions between striatal $A_{2A}R$ and CB₁R have been reported, and evidence supports that this cross-talk may rely, at least in part, on the formation of $A_{2A}R$ -CB₁R heteromeric complexes. However, the specific location and properties of these heteromers have remained largely unknown. Here, by using techniques that allowed a precise visualization of the heteromers *in situ* in combination with sophisticated genetically modified animal models, together with biochemical and pharmacological approaches, we provide a high-resolution expression map and a detailed functional characterization of $A_{2A}R$ -CB₁R heteromer (i) is essentially absent from corticostriatal projections and striatonigral neurons, and, instead, is largely present in striatopallidal neurons, (ii) displays a striking G protein-coupled signaling profile, where co-stimulation of both receptors leads to strongly reduced downstream signaling, and (iii) undergoes an unprecedented dysfunction in Huntington's disease, an archetypal disease that affects striatal neurons. Altogether, our findings may open a new conceptual framework to understand the role of coordinated adenosine-endocannabinoid signaling in the indirect striatal pathway, which may be relevant in motor function and neurodegenerative diseases.

Neuropsychopharmacology (2018) 43, 964–977; doi:10.1038/npp.2017.12; published online 15 February 2017

Received 4 July 2016; revised 13 January 2017; accepted 14 January 2017; accepted article preview online 19 January 2017

INTRODUCTION

The dorsal striatum is a key node for many neurobiological processes such as motor activity, cognitive functions, and affective processes. The vast majority (~95%) of neurons within the striatum are GABAergic medium spiny neurons (MSNs), which receive glutamatergic inputs primarily from the cortex. MSNs differ in their neurochemical composition and form two major efferent pathways, the direct (striatonigral) pathway and the indirect (striatopallidal) pathway (Kreitzer, 2009). The proper functioning of MSNs relies critically on metabotropic receptor signaling. Many neurotransmitters and neuromodulators such as dopamine,

^{*}Correspondence: Dr C Lluís, Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona 08028, Spain, Tel: +34 93 4021208, Fax: +34 93 4021559, E-mail: clluis@ub.edu or Dr PJ McCormick, School of Veterinary Medicine Faculty of Health & Medical Sciences, University of Surrey, Daphne Jackson Road, Guildford, Surrey, GU2 7AL, UK, Tel: +44 (0)1483 684399, Fax: +44 (0)1483 684399, E-mail: p.mccormick@surrey.ac.uk or Professor M Guzmán, Instituto Universitario de Investigación Neuroquímica (IUIN) and Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid 28040, Spain, Tel: +34 91 3944668, Fax: +34 91 3944672, E-mail: mguzman@quim.ucm.es

glutamate, endocannabinoids and adenosine control MSN activity and plasticity by engaging their cognate G proteincoupled receptors (GPCRs) (Lovinger, 2010; Girault, 2012). Specifically, the main endocannabinoid and adenosine receptors present in MSNs, ie, cannabinoid type 1 receptor (CB_1R) and adenosine subtype 2A receptor $(A_{2A}R)$, are of pivotal importance in the control of neuronal excitability. CB₁R is one of the most abundant GPCRs in MSNs (Glass et al, 2000; Castillo et al, 2012). In particular, CB₁R is highly expressed in the terminals of both striatonigral and striatopallidal MSNs, where it mediates endocannabinoiddependent inhibition of GABA release, thus decreasing motor activity (Katona and Freund, 2008; Castillo et al, 2012). CB₁R is also expressed in glutamatergic terminals projecting from the cortex onto the striatum, where it controls MSN function by blunting glutamatergic output and mediating the so-called endocannabinoid-dependent longterm depression (Kreitzer, 2009; Castillo et al, 2012). A2AR is also very abundant in the striatum (Schiffmann and Vanderhaeghen, 1993; Schiffmann et al, 2007). Presynaptically, a significant fraction of the corticostriatal projections that expresses CB_1R also contains $A_{2A}R$. These $A_{2A}R$ molecules are mostly located on corticostriatal terminals that form synaptic contacts with striatonigral MSNs (Quiroz et al, 2009; Ferreira et al, 2015). Blockade of presynaptic A2AR counteracts glutamate release and motor output evoked by cortical stimulation (Quiroz et al, 2009; Orru et al, 2011; Tebano et al, 2012). Postsynaptically, A2AR is selectively located on striatopallidal MSNs, which co-express dopamine D₂ receptor (D₂R) (Schiffmann et al, 2007; Azdad et al, 2009; Tebano et al, 2012). Blockade of postsynaptic A_{2A}R mediates the motor-activating effects of A_{2A}R antagonists, consistent with an inactivation of the indirect pathway (Orru et al, 2011; Tebano et al, 2012).

The high expression of $A_{2A}R$ and CB_1R in the striatum, together with the key involvement of both receptors in the control of motor and goal-directed behaviors, have led to a large number of studies on the interactions between them (Ferre et al, 2010; Tebano et al, 2012). Understanding these interactions is of special relevance not only physiologically but also pharmacologically as these receptors are targets of widely consumed psychoactive substances such as caffeine (an A2AR antagonist) and Δ^9 -tetrahydrocannabinol (a CB₁R agonist). Both facilitatory and inhibitory functional interactions between striatal A2AR and CB1R have been demonstrated (Ferre et al, 2010; Tebano et al, 2012; Justinova et al, 2014). The precise molecular mechanisms underlying the cross-talk between these receptors is yet to be fully understood, but some evidence supports that they may rely, at least in part, on the formation of A2AR-CB1R heteromeric complexes (Carriba et al, 2007; Ferre et al, 2010; Tebano et al, 2012; Chiodi et al, 2016). Despite >10 years of research on GPCR heteromers, there continues to be a major gap in our understanding of where exactly heteromers are expressed as well as linking them to precise signal transduction pathways and biological functions. In the case of the $A_{2A}R$ -CB₁R heteromer, factors to consider include (i) the additional partners with which $A_{2A}R$ and CB₁R could interact differently at presynaptic sites (eg, A_1R) (Ciruela *et al*, 2006) or postsynaptic sites (eg, D_2R and mGluR₅) (Navarro et al, 2008; Azdad et al, 2009; Cabello et al, 2009; Bonaventura et al, 2014; Bonaventura et al, 2015), (ii) the convergence of adenosine and endocannabinoid actions on various intracellular signaling pathways (Ferre *et al*, 2010; Tebano *et al*, 2012), and (iii) the intricate network of molecular processes controlling adenosine and endocannabinoid release (Kreitzer and Malenka, 2005; Lerner *et al*, 2010).

Previous studies on the A_{2A}R-CB₁R heteromer have relied essentially on energy transfer-based assays in cells ectopically expressing A_{2A}R and CB₁R, as well as co-immunolocalization and co-immunoprecipitation experiments (Carriba et al, 2007; Navarro et al, 2008; Bonaventura et al, 2014). These approaches, although widely exploited and certainly valuable, possess limitations of spatial resolution (co-immunolocalization), molecular specificity (co-immunoprecipitation), and biological interpretation (energy transfer using protein overexpression) to characterize GPCR heteromers. Hence, here we made use of techniques to allow a precise visualization of the heteromers in situ in combination with sophisticated genetically modified mouse models, together with biochemical and pharmacological approaches, to cogently characterize the anatomy and signaling profile of the A_{2A}R-CB₁R heteromer in the dorsal striatum.

MATERIALS AND METHODS

The experimental procedures used in this study are extensively described in Supplementary Materials and Methods. That section provides precise details on animal models (genetic mouse models to study the location of the $A_{2A}R$ - CB_1R heteromer, as well as mouse models of Huntington's disease (HD)), human *post mortem* brain samples (see also Supplementary Table S1), recombinant adeno-associated viral vectors, HIV TAT peptides designed to disrupt the $A_{2A}R$ - CB_1R heteromer, cell culture and transfection procedures, *in situ* proximity ligation assays (PLA), fluorescence complementation assays, cAMP and Ca²⁺ concentration assays, western blotting assays, immunomicroscopy procedures, and statistical analyses (see also Supplementary Table S2).

RESULTS

A_{2A}R-CB₁R Heteromers are Located on GABAergic Neurons Rather Than Glutamatergic Projections in the Mouse Dorsal Striatum

To clarify the precise location of A2AR-CB1R heteromers in the dorsal striatum we conducted PLA experiments. The PLA assay is a powerful and straightforward technique to detect protein-protein interactions in general, and GPCR oligomers in particular, and to localize these complexes in situ with cell sub-population selectivity, thus allowing an unbiased demonstration and quantification of protein complexes in unmodified cells and tissues (Taura et al, 2015). Importantly, PLA permits assessing close proximity between proteins within an oligomer with high resolution (<40 nm). As PLA relies on the amplification of a small signal, its main limitation is antibody specificity/background noise, which we minimize by adapting refined technical protocols as well as employing multiple genetic mouse models and controls (Taura et al, 2015). Here, we first used conditional mutant mice bearing a genetic deletion of CB_1R in forebrain GABAergic neurons $(CB_1R^{floxed/floxed;Dlx5/6-Cre/+}$ mice; herein referred to as GABA- $CB_1R^{-/-}$ mice) or dorsal telencephalic glutamatergic neurons




Figure 1 $A_{2A}R$ -CB₁R heteromers are located on GABAergic neurons rather than glutamatergic projections in the mouse dorsal striatum. (a, b) PLA assays were performed in dorsal-striatum sections from 3–4-month-old mice of different genotypes. $A_{2A}R$ -CB₁R heteromers are shown as green dots. Nuclei are colored in blue by DAPI staining. (a) Representative low-magnification image of tissue sections used for PLA assays. Left, DAPI-stained field; right, bright field. Scale bar: 1 mm. Representative pictures from control CB₁R-floxed, GABA-CB₁R^{-/-}, Glu-CB₁R^{-/-}, and GABA-Glu-CB₁R^{-/-} mice. Scale bar: 20 μ m. (b) Representative pictures from Stop-CB₁R, GABA-CB₁R-RS mice, Glu-CB₁R-RS mice and CB₁R-RS mice. Scale bar: 20 μ m. (c) Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the mean \pm SEM of counts in 5–14 different fields from three different animals of each type. One-way ANOVA followed by Dunnet *post hoc* test showed a significant (*p < 0.05, ***p < 0.001) decrease of heteromer expression compared to control CB₁R-floxed mice (a) or to CB₁R-RS mice (b). Further details of statistical analyses are given in Supplementary Table S2.

 $(CB_1R^{floxed/floxed;Nex-Cre/+}$ mice; herein referred to as $Glu-CB_1R^{-/-}$ mice) (Monory *et al*, 2006). Striatal $A_{2A}R$ - CB_1R heteromers were evident almost exclusively as dots in the vicinity of cell nuclei, and showed a remarkable reduction in GABA-CB₁R^{-/-} mice (Figure 1a and c). In contrast, no significant differences were observed between $Glu-CB_1R^{-/-}$ mice and $CB_1R^{floxed/floxed;+/+}$ controls (Figure 1a and c) when data were expressed either as a percentage of cells containing one or more dots relative to total cell nuclei (Figure 1c) or as a total number of dots relative to total cell nuclei ($CB_1R^{floxed/floxed}$ mice: 2.23 ± 0.16 ; $Glu-CB_1R^{-/-}$ mice: 2.40 ± 0.20 ; n=3 animals of each genotype). In addition,

Glu-CB₁R^{-/-} mice did not show any significant reduction in the percentage of A_{2A} R-CB₁R heteromer-positive cells relative to total cell nuclei in their motor cortices (CB₁R^{floxed/floxed} mice: 70.3 ± 2.3; Glu-CB₁R^{-/-} mice: 71.4 ± 3.0; *n* = 3 animals of each genotype). Likewise, the expression levels of A_{2A} R-CB₁R heteromers displayed by GABA-CB₁R^{-/-} mice were not decreased further when the CB₁R gene was simultaneously ablated in glutamatergic neurons (CB₁R^{floxed/floxed;Dlx5/6-Cre;Nex-Cre} mice; herein referred to as GABA-Glu-CB₁R^{-/-} mice) (Bellocchio *et al*, 2010) (Figure 1a and c). Control experiments conducted in the absence of one of the two primary antibodies, as well as in full CB₁R^{-/-} mice (Marsicano *et al*, 2002) and full $A_{2A}R^{-/-}$ mice (Ledent *et al*, 1997), provided strong support to the specificity of the PLA analyses performed (Supplementary Figure S1a–c). Of note, a different anti-CB₁R primary antibody provided a similar $A_{2A}R$ -CB₁R heteromer detection (Supplementary Figure S1d). Moreover, the specificity of the primary antibodies used was also demonstrated by immunocytofluorescence studies conducted in HEK-293T cells transfected or not with cDNAs encoding human $A_{2A}R$ or human CB₁R (Supplementary Figure S1e).

To unequivocally ascribe A2AR-CB1R heteromers to GABAergic neurons we made use of a Cre-mediated, lineage-specific CB₁R re-expression/rescue strategy in a CB₁R-null background (herein referred to as Stop-CB₁R mice) (Ruehle et al, 2013; De Salas-Quiroga et al, 2015). The selective rescue of CB₁R expression in forebrain GABAergic neurons (herein referred to as GABA-CB1R-RS mice) was achieved by expressing Cre under the regulatory elements of the Dlx5/6 gene (De Salas-Quiroga et al, 2015). In parallel, we rescued CB₁R expression selectively in dorsal telencephalic glutamatergic neurons (herein referred to as Glu-CB₁R-RS mice) by using a Nex-Cre mouse line (Ruehle *et al*, 2013). As a control, an EIIa-Cre-mediated, global CB1R expression-rescue in a CB₁R-null background was conducted (herein referred to as CB1R-RS mice) (Ruehle et al, 2013). Remarkably, the expression levels of A_{2A}R-CB₁R heteromers were notably restored in GABA-CB₁R-RS mice (Figure 1b and c). In contrast, no significant rescue of the heteromer was observed in Glu-CB1R-RS animals when data were expressed either as a percentage of cells containing one or more dots relative to total cell nuclei (Figure 1c) or as a total number of dots relative to total cell nuclei (Stop-CB₁R mice: 0.24 ± 0.01 ; Glu-CB₁R-RS mice: 0.28 ± 0.04 ; n = 3 animals of each genotype).

Taken together, these data strongly support that, in the mouse dorsal striatum, $A_{2A}R$ -CB₁R heteromers are located on GABAergic neurons rather than glutamatergic projections.

A_{2A}R-CB₁R Heteromers are Located on Indirect-Pathway MSNs in the Mouse Dorsal Striatum

The vast majority (~95%) of neurons within the striatum are MSNs (Kreitzer, 2009). These neurons differ in their neurochemical composition and form two major efferent pathways. The direct pathway consists of MSNs expressing markers such as dopamine D_1 receptor (D_1R) and substance P. It mainly projects to the substantia nigra pars reticulata and the internal segment of the globus pallidus. The indirect pathway is composed of MSNs expressing markers such as D₂R and enkephalin. It mainly projects to the external segment of the globus pallidus, which, in turn, projects to the subthalamic nucleus (Kreitzer, 2009). CB1R is located on both direct-pathway and indirect-pathway MSNs, whereas A2AR resides essentially on indirect-pathway MSNs (Schiffmann et al, 2007; Kreitzer, 2009; Castillo et al, 2012). As a consequence, A_{2A}R-CB₁R heteromers would conceivably be located on indirect-pathway MSNs. To substantiate this possibility, we first used conditional mutant mice bearing a genetic deletion of CB_1R in D_1R -expressing neurons ($CB_1R^{floxed/floxed;Drd1a-Cre/+}$ mice; herein referred to as $D_1R-CB_1R^{-/-}$ mice) (Monory *et al*, 2007). No differences were observed in the expression of $A_{2A}R\mathchar`-CB_1R$ heteromers, as assessed by PLA analyses, between $D_1R-CB_1R^{-\prime-}$ mice and control mice (Supplementary Figure S2a), thus confirming that the heteromer is not located on direct-pathway MSNs. CB_1R is essentially a presynaptic receptor that, in MSNs, resides, mainly on terminals and collaterals (Katona and Freund, 2008; Kreitzer, 2009; Castillo et al, 2012). Hence, we also studied the projection sites of MSNs in $CB_1 R^{floxed/floxed}$ mice. Specifically, we injected stereotactically these CB₁R^{floxed/floxed} mice with a recombinant adenoassociated viral vector encoding Cre (or EGFP to gain visualization of neuronal projections) into the dorsal striatum (or the motor cortex as control). Cre expression was driven by a CaMKIIa promoter, so it was confined to MSNs (injections into the striatum) or principal neurons (injections into the cortex) (Chiarlone et al, 2014). Cre-mediated excision of the *loxP*-flanked CB_1R gene in dorsal-striatum MSNs of $CB_1R^{floxed/floxed}$ mice reduced the expression of A2AR-CB1R heteromers in the globus pallidus (Supplementary Figure S2b). In contrast, inactivation of the CB_1R gene in the motor cortices of $CB_1R^{floxed/floxed}$ mice did not affect the expression of A2AR-CB1R heteromers on corticostriatal inputs (Supplementary Figure S2c).

Collectively, these data show that, in the mouse dorsal striatum, $A_{2A}R$ -CB₁R heteromers are primarily located on indirect-pathway MSNs.

$A_{2A}R$ -CB₁R Heteromers Expressed in the Mouse Dorsal Striatum are Functional

Previous reports have shown the existence of both facilitatory and inhibitory functional interactions between A2AR and CB₁R (Ferre *et al*, 2010; Tebano *et al*, 2012). To investigate the possible role of the A2AR-CB1R heteromer in these interactions we characterized in detail heteromer functionality in the dorsal striatum. For this purpose we used C57BL/6N-mouse striatal slices and conducted cell signaling experiments on two pathways coupled to A2AR and CB1R: extracellular signalregulated kinase (ERK) and Akt. The CB1R agonist WIN--55,212-2 or the A2AR agonist CGS21680 increased ERK phosphorylation (activation) in the dorsal striatum, whereas co-incubation with both agonists abrogated ERK phosphorylation, thus demonstrating a negative cross-talk between $A_{2A}R$ and CB_1R (Figure 2a). In addition, the CB_1R antagonist SR141716 (rimonabant) or the A2AR antagonist ZM241385 prevented the ERK-activating effect of WIN-55,212-2 or CGS21680 (Figure 2a). These data show a cross-antagonism between the two receptors, a phenomenon not uncommon in heteromers. When these cross-pharmacological assays were conducted for Akt phosphorylation (activation), similar negative cross-talk and cross-antagonism processes were observed (Figure 2a). Collectively, these findings demonstrate the existence of inhibitory interactions between A2AR and CB_1R in the mouse dorsal striatum.

Next, we sought to substantiate that the aforementioned negative cross-talk and cross-antagonism between $A_{2A}R$ and CB_1R rely on $A_{2A}R$ - CB_1R heteromers. It is generally believed that agonist binding to the extracellular pocket of GPCRs induces local conformational changes that increase signaling by opening an intracellular cavity via the movement of transmembrane helices (TMs) 5 and 6 for receptor activation, whereas, conversely, inverse agonists decrease the basal, agonist-independent, level of signaling by closing this cavity (Shoichet and Kobilka, 2012; Venkatakrishnan *et al*, 2013). In

A_{2A}R-CB₁R heteromers in the dorsal striatum E Moreno et al




Figure 2 $A_{2A}R$ -CB₁R heteromers expressed in the mouse dorsal striatum are functional. (a, c) ERK and Akt phosphorylation was determined in striatal slices from 3–4-month-old C57BL/6N mice pre-treated for 4 h with medium (a) or with 4 µM TM5, TM6 or TM7 peptides alone or in combination (c). Slices were then preincubated for 20 min with vehicle, the CB₁R antagonist SR141716 (10 µM) or the $A_{2A}R$ antagonist ZM241385 (10 µM) before the addition of vehicle, the CB₁R agonist WIN-55,212-2 (1 µM), the $A_{2A}R$ agonist CGS21680 (1 µM) or both, for 10 min. Immunoreactive bands from 3–6 slices from 12 different animals were quantified for each condition. Values represent mean \pm SEM of percentage of phosphorylation relative to basal levels found in vehicle antagonist treatment over agonist-only treatment ($^{#}p < 0.01$, $^{##}p < 0.01$). Further details of statistical analyses are given in Supplementary Table S2. In (a), representative western blots are shown at the top of each panel. (b) Schematic representation of the bimolecular fluorescence complementary Table S2. In (a), representative western blots are shown at the top of each panel. (b) Schematic representation of the bimolecular fluorescence complementary Table S2. In (a), representative western blots are shown at the top of each panel, fluorescence at 530 nm was monitored in HEK-293T cells transfected with the indicated amounts of cDNA encoding CB₁R-nYFP and A_{2A}R-cYFP (equal amount for each construct) or, as a negative control, transfected with cDNA encoding CB₁R-nYFP and the non-interacting D₁R-cYFP. Transfected cells were treated for 4 h with medium or with 4 µM TM5, TM6, and/or TM7 peptides before fluorescence reading. Values represent mean \pm SEM of percentage of fluorescence relative to A_{2A}R-cYFP/CB₁R-nYFP maximal complementation (n=4-12 replicates from three independent experiments for each condition). One-way ANOVA showed a significant change in fluorescence over non-intransfected cells (**p < 0.01), **p < 0.00), or of

fact, the reported crystal structure of the agonist-bound A_{2A}R, compared with the inactive, antagonist-bound A_{2A}R, shows an outward tilt and rotation of the cytoplasmic half of TM6 and a movement of TM5, thus resembling the changes associated with the active-state structure of other class A GPCRs (Xu et al, 2011). Likewise, the crystal structure of the antagonist-bound CB₁R has been recently reported, showing a similar opsin-like behavior for this receptor (Hua et al, 2016; Shao et al, 2016). Our aforementioned observation that A2AR-CB₁R heteromers display both negative cross-talk and crossantagonism suggests a negative modulation between both receptors through protein-protein interactions involving the TM5/TM6 interface. Hence, to test this hypothesis, we studied whether synthetic peptides with the sequence of TM5, TM6 or TM7 (as negative control) of CB₁R, fused to HIV TAT peptide to allow efficient intracellular delivery and plasma membrane insertion (Schwarze et al, 1999; He et al, 2011), were able to disrupt A_{2A}R-CB₁R heteromerization and the observed bidirectional cross-signaling. This approach has been recently used by us and others to disrupt other heteromers (Guitart et al. 2014; Lee et al, 2014; Viñals et al, 2015).

We first characterized the TM interference peptides by the bimolecular fluorescence complementation technique. In this assay, fluorescence only appears after correct folding of two YFP Venus hemiproteins. This occurs when two receptors fused to hemi-YFP Venus proteins (cYFP or nYFP) come within proximity to facilitate YFP Venus folding (Figure 2b, scheme). Fluorescence was detected in HEK-293T cells transfected with different amounts of cDNA encoding CB₁R-nYFP and A_{2A}R-cYFP, but not in negative controls in which cells were transfected with cDNA encoding CB₁RnYFP and the non-interacting D₁R-cYFP (Figure 2b). The TM-targeted peptides were subsequently tested. We found that treatment of cells expressing CB₁R-nYFP and A_{2A}RcYFP with TM5 or TM6 (but not TM7) peptides disrupted the heteromer structure, as revealed by a loss of fluorescence (Figure 2b). We next studied the effect of the interference peptides on A_{2A}R and CB₁R signaling in mouse striatal slices. When the peptides were evaluated in cross-pharmacological assays, we found that pretreatment of brain slices with TM5, TM6 or both (but not TM7) peptides disrupted (i) the ability of the CB₁R agonist WIN-55,212-2 and the CB₁R antagonist SR141716 to dampen A2AR-evoked actions on ERK and Akt, as well as (ii) the ability of the A2AR agonist CGS21680 and the A_{2A}R antagonist ZM241385 to dampen CB₁R-evoked actions on these two signaling pathways (Figure 2c). Of note, when the TM5 and TM6 peptides were used in combination, the increase in ERK and Akt phosphorylation upon receptor co-activation tended to be higher compared with TM5-only or TM6-only incubations (Figure 2c), thus conceivably reflecting that the peptide combination is more efficient than each peptide alone in disrupting the heteromer.

Together, these data provide evidence for the importance of the TM5/TM6 interface in the $A_{2A}R$ -CB₁R heteromer, and support that the negative cross-talk and cross-antagonism that occurs between CB₁R and $A_{2A}R$ are due to protein-protein interactions and are a specific biochemical characteristic of the $A_{2A}R$ -CB₁R heteromer.

Functional A_{2A}R-CB₁R Heteromers are Present in Wild-Type and Mutant Huntingtin-Expressing Striatal Neuroblasts


To evaluate the relevance of the $A_{2A}R-CB_1R$ heteromer in a pathological setting we selected HD as a model because (i) it is the paradigmatic disease primarily caused by a selective loss of MSNs in the dorsal striatum (Walker, 2007), and (ii) changes in the expression and function of $A_{2A}R$ and CB_1R have been shown to occur in the dorsal striatum of patients and animal models of the disease (Glass *et al*, 2000; Fernandez-Ruiz *et al*, 2011; Lee and Chern, 2014). We first characterized the heteromer in conditionally immortalized striatal neuroblasts expressing two normal (STHdh^{Q7}) or mutant (STHdh^{Q111}) fullength endogenous huntingtin alleles with 7 or 111 glutamine residues, respectively, which represent a widely accepted cellular model to investigate huntingtin actions. These cells do not exhibit mutant-huntingtin inclusions (Trettel *et al*, 2000), thus allowing the modeling of changes occurring at early HD stages.

We readily detected PLA-positive A_{2A}R-CB₁R heteromers in both STHdh^{Q7} and STHdh^{Q111} cells (Figure 3a), indicating that the mere expression of mutant huntingtin does not prevent heteromerization of both receptors. To evaluate the functional characteristics of A_{2A}R-CB₁R heteromers, we first measured the global cellular response using DMR label-free assays, which detect changes in light diffraction in the bottom 150 nm of a cell monolayer. In these experiments we had a preference for CP-55,940 over WIN-55,212-2 as the CB₁R agonist because the former is less hydrophobic than the latter and so conceivably more accessible to cultured cells. In fact, dose-response experiments conducted in both STHdhQ7 and STHdhQ111 cells showed that CP-55,940 impacted the DMR signal more markedly than WIN-55,212-2 (Supplementary Figure S3a and b). Both the A2AR agonist CGS21680 and the CB1R agonist CP-55,940 induced time-dependent signaling in STHdh^{Q7} and STHdh^{Q111} cells (Figure 3b). Of note, A_{2A}R and CB₁R-evoked signaling was essentially insensitive to pertussis toxin (PTX) or cholera toxin (CTX) (Figure 3b), thus indicating that these receptors do not significantly couple to G_i or G_s proteins in these cells. This notion was further supported by the observation that, in both STHdh^{Q7} cells (Supplementary Figure S4a) and STHdh^{Q111} cells (Supplementary Figure S4b), neither the A2AR agonist nor the CB1R agonist was able to affect basal or forskolin-elevated cAMP concentrations in the absence or presence of PTX or CTX. In line with this apparent lack of 'classical' A_{2A}R-G_{s/olf} and CB₁R-G_i coupling, the G_q protein inhibitor YM-254890 was able to abrogate the A_{2A}R and CB1R-evoked changes in DMR (Figure 3c). This nonconventional coupling did appear to be due to heteromer formation as experiments conducted with the TM5 and TM6 peptides on STHdh $^{\rm Q7}$ and STHdh $^{\rm Q111}$ cells showed that the peptide combination, presumably by disrupting the heteromer, turned A_{2A}R and CB₁R action to their 'classical', 'protomeric' G_{s/olf}, and G_i-mediated signaling, respectively (Supplementary Figure S4c). This strongly supports that there is no limitation of G_{s/olf} or G_i protein availability in these cells, as previously indicated by others' work (Araki et al, 2006), and that the A_{2A}R-CB₁R heteromer couples selectively to G_q. Moreover, and further supporting a G_q-dependent signaling for the heteromer, engagement of A2AR or CB1R increased intracellular free Ca2+ concentration in both STHdhQ7 and STHdhQ111 cells (Supplementary Figure S5).

970

We next investigated whether the heteromer-specific biochemical properties described above could influence G_{q} -driven signaling. Regarding negative cross-talk, the DMR

signal induced by the A_{2A}R agonist CGS21680 alone or the CB₁R agonist CP-55,940 alone was attenuated when both agonists were added together to STHdh^{Q7} or STHdh^{Q111} cells



Neuropsychopharmacology

(Figure 3d, top panels). Regarding cross-antagonism, the DMR signal induced by the CB₁R agonist was prevented not only by the CB₁R antagonist SR141716 but also by the A_{2A}R antagonist ZM241385, and, similarly, the DMR signal induced by the A_{2A}R agonist CGS21680 was also prevented by either antagonist (Figure 3d, bottom panels). Of note, the combination of the TM5 and TM6 peptides disrupted the cross-antagonism between A_{2A}R and CB₁R in STHdh^{Q7} and STHdh^{Q111} cells (Figure 3d, bottom panels).

Collectively, these data indicate that co-expression of $A_{2A}R$ and CB_1R , likely through the formation of $A_{2A}R-CB_1R$ heteromers, facilitates G_q rather than G_s or G_i coupling in wild-type and mutant huntingtin-expressing mouse striatal neuroblasts.

Functional A_{2A}R-CB₁R Heteromers are Expressed in HD Mice at Early but not Advanced Disease Stages

To study the role of A_{2A}R-CB₁R heteromers in HD in vivo we analyzed their expression and function in a widely accepted model of HD, heterozygous mutant knock-in Hdh^{Q7/Q111} mice, that express in heterozygosity a mutant full-length huntingtin allele with 111 glutamine residues, and wild-type Hdh^{Q7/Q7} mice, that express two wild-type full-length huntingtin alleles with 7 glutamine residues. At an early stage of the disease (4 months of age), mutant HdhQ7/Q111 mice displayed $A_{2A}R$ -CB₁R heteromers in the dorsal striatum at similar levels as wild-type Hdh^{Q7/Q7} mice (Figure 4a). However, at more advanced stages (6 and 8 months of age), the expression of $A_{2A}R-CB_1R$ heteromers was almost completely lost in mutant Hdh^{Q7/Q111} mice but not wild-type Hdh^{Q7/Q7} mice (Figure 4a). Of note, total striatal A2AR and CB1R expression, as determined by western blot (Supplementary Figure S6a) and immunofluorescence microscopy (Supplementary Figure S6b), was largely pre-served in 6-month-old mutant Hdh^{Q7/Q111} mice compared with age-matched wild-type Hdh^{Q7/Q7} mice. Hence, irrespective of the small differences found between the western blot and immunofluorescence data, which can be conceivably due to the intrinsic characteristics of the two techniques, these findings suggest that the massive loss of A_{2A}R-CB₁R heteromers found in Hdh^{Q7/Q111} mice is mostly heteromer-selective and not primarily due to a mere reduction of total A2AR and CB1R molecules. In agreement with this notion, and as a further proof of the selective loss, the expression of another CB₁R heteromer previously reported in indirect-pathway MSNs, namely CB1R-D2R (Navarro *et al*, 2008; Bonaventura *et al*, 2014), was not reduced in 6-month-old mutant $Hdh^{Q7/Q111}$ mice compared with their wild-type controls (Supplementary Figure S6c). Moreover, a remarkable loss of $A_{2A}R$ -CB₁R heteromers was also observed in advanced stages of mouse models of HD transgenic for human mutant huntingtin exon 1, specifically R6/1 mice (Supplementary Figure S7a) and R6/2 mice (Supplementary Figure S7b). Again, the expression of CB₁R-D₂R heteromers, used as a control, did not decrease in advanced-stage R6/1 or R6/2 mice compared with agematched wild-type animals (Supplementary Figure S7c).

CB₁R is highly abundant in most MSNs (Katona and Freund, 2008; Castillo et al, 2012), but it has been reported that the downregulation of CB₁R mRNA expression in R6 transgenic mice is striatum subregion-selective, occurring preferentially in the dorsolateral than the dorsomedial striatum (Denovan-Wright and Robertson, 2000; McCaw et al, 2004). Hence, we analyzed the expression of total $A_{2A}R$ and CB1R immunoreactivity, as well as that of the A2AR- CB_1R heteromer, in the dorsolateral vs the dorsomedial striatum of wild-type Hdh^{Q7/Q7} and mutant Hdh^{Q7/Q111} mice at 6 months of age. We found no significant differences between the two dorsal-striatum compartments in total A2AR immunoreactivity in either Hdh^{Q7/Q7} mice (relative values: dorsolateral: 100 ± 5.7 ; A_{2A}R, dorsomedial: 101.8 ± 5.7 ; n = 3 animals) or Hdh^{Q7/Q111} mice (relative values: dorsolateral: 100 ± 5.2 ; A_{2A}R, dorsomedial: 114.8 ± 7.8 ; n = 3 animals). There was a moderate preference of total CB₁R protein expression for the dorsolateral striatum in HdhQ7/Q7 mice (relative values: dorsolateral: 100 ± 3.8 ; dorsomedial: 83.1 ± 2.5; n=3 animals; p=0.032), as well as a non-significant trend in Hdh^{Q7/Q111} mice (relative values: dorsolateral: 100 ± 2.9 ; dorsomedial: 85.8 ± 2.7 ; n=3 animals). Regarding the A2AR-CB1R heteromer, we found no significant differences between the two dorsal-striatum compartments in the percentage of heteromer-positive cells relative to total cell nuclei in either $Hd\hat{h}^{Q7/Q7}$ mice (dorsolateral: 45.0 ± 4.9 ; dorsomedial: 44.0 ± 3.8 ; n=3 animals) or Hdh^{Q7/Q111} mice (dorsolateral: 10.4 ± 2.3 ; dorsomedial: 7.5 ± 1.4 ; n = 4 animals). Overall, these data show that the A_{2A}R-CB₁R heteromer has a rather similar expression pattern in the mouse dorsolateral and dorsomedial striatum.

To study the function of the $A_{2A}R$ -CB₁R heteromer in HD mice, we performed cross-signaling experiments in striatal slices from 6-month-old Hdh^{Q7/Q7} and Hdh^{Q7/Q111} mice. Consistently with the aforementioned data on both cell and slice cultures from control C57BL/6N mice, dual agonist treatment with WIN-55,212-2 and CGS21680 depressed phospho-ERK or phospho-Akt signal compared with single-agonist stimulation in wild-type Hdh^{Q7/Q7} mice, thus showing a negative cross-talk (Figure 4b and c). In addition,

Figure 3 $A_{2A}R-CB_1R$ heteromers expressed in wild-type STHdh^{Q7} and mutant huntingtin-expressing STHdh^{Q111} striatal neuroblasts signal via G_q protein rather than G_i or G_s protein. (a) PLA assays were performed in STHdh^{Q7} and STHdh^{Q111} cells. $A_{2A}R-CB_1R$ heteromers are shown as green dots. Nuclei are colored in blue by DAPI staining. Controls in the absence of anti- $A_{2A}R$ primary antibody were also performed. Representative pictures are shown. Scale bar: 20 µm. (b) Dynamic mass redistribution (DMR) assays were performed in STHdh^{Q7} and STHdh^{Q111} cells pretreated overnight with vehicle, pertussis toxin (PTX; 10 ng/ml) or cholera toxin (CTX; 100 ng/ml), and further treated with vehicle, the $A_{2A}R$ agonist CGS21680 (1 µM) or the CB₁R agonist CP-55,940 (1 µM). (c) DMR assays in STHdh^{Q7} and STHdh^{Q111} cells preincubated for 30 min with vehicle or the G_q protein inhibitor YM-254890 (1 µM), and then activated with the $A_{2A}R$ agonist CGS21680 (1 µM) or the CB₁R agonist CP-55,940 (1 µM). (d) DMR assays showing negative cross-talk (top panels) and crossantagonism (bottom panels) between $A_{2A}R$ and CB₁R signaling. STHdh^{Q7} and STHdh^{Q111} cells were not pre-treated (top panels) or pre-treated for 4 h with medium (left bottom panels) or with 4 µM TM5 plus TM6 (right bottom panels) before incubation for 30 min with vehicle, the CB₁R antagonist SR141716 (RIM; 1 µM) or the $A_{2A}R$ antagonist ZM241385 (1 µM), and then activated with vehicle, CGS21680 (1 µM) or CP-55,940 (1 µM). (b–d) The resulting shifts of reflected light wavelength (pm) were monitored over time. Each panel is a representative experiment of n = 3 different experiments. Each curve is the mean of a representative optical trace experiment carried out in triplicates.




Figure 4 Functional $A_{2A}R$ -CB₁R heteromers are expressed in Hdh^{Q7/Q111} HD mice at early but not advanced disease stages. (a) PLA assays were performed in dorsal-striatum sections from wild-type Hdh^{Q7/Q7} mice and mutant huntingtin-expressing knock-in Hdh^{Q7/Q111} mice. $A_{2A}R$ -CB₁R heteromers are shown as green dots in mice at 4, 6, and 8 months of age. Nuclei are colored in blue by DAPI staining. Representative pictures are shown. Scale bar: 20 µm. Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the mean \pm SEM of counts in 11–26 different fields from five different animals of each type. One-way ANOVA followed by Bonferroni *post hoc* test showed showed a significant (****p* < 0.001) decrease of heteromer expression in Hdh^{Q7/Q111} compared with the respective age-matched Hdh^{Q7/Q7} mice. (b–e) ERK phosphorylation (b, d) and Akt phosphorylation (c, e) were determined in striatal slices from 6 month-old wild-type Hdh^{Q7/Q7} mice (b, c) and mutant huntingtin-expressing knock-in Hdh^{Q7/Q111} mice (d, e). Slices were preincubated for 20 min with vehicle, the CB₁R antagonist SR141716 (RII; µM) or the $A_{2A}R$ antagonist ZM241385 (1 µM) before the addition of vehicle or the CB₁R agonist WIN-55,212-2 (1 µM), the $A_{2A}R$ agonist CGS21680 (1 µM), or both, for 10 min. Immunoreactive bands from 4–6 slices of 5–6 different animals were quantified for each condition. Values represent mean \pm SEM of percentage of phosphorylation relative to basal levels found in vehicle only-treated slices (100%, dotted line). Representative western blots are shown at the top of each panel. One-way ANOVA showed a significant effect over basal (**p* < 0.05, "**p* < 0.01, ****p* < 0.001), or of the antagonist plus agonist treatment over the agonist-only treatment (*[#]*p* < 0.05, "#*p* < 0.01]. Further details of statistical analyses are given in Supplementary Table S2.




Figure 5 $A_{2A}R-CB_1R$ heteromers are lost in the caudate-putamen of high-grade HD patients. PLA assays were performed in caudate-putamen sections of post mortem samples from control subjects (a) and HD patients at different grades (b–f). $A_{2A}R-CB_1R$ heteromers are shown as green dots. Nuclei are colored in blue by DAPI staining. Representative pictures are shown. Scale bar: 20 µm. (g) Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the mean ± SEM of counts in 21–43 different fields from five control subjects, five low-grade HD patients (1 grade 0, 2 grade 1, plus 2 grade 2) and five high-grade HD patients (2 grade 3, plus 3 grade 4). The characteristics of these human samples are shown in Supplementary Table S1. One-way ANOVA followed by Dunnet *post hoc* test showed a significant (***p < 0.001) decrease of heteromer expression compared to control subjects. Further details of statistical analyses are given in Supplementary Table S2. (h) Scheme depicting the proposed location and G protein-coupling of the $A_{2A}R-CB_1R$ heteromer in the dorsal striatum. It is currently believed (*left*) that the $A_{2A}R-CB_1R$ heteromer is located on corticostriatal projections as well as on the somatodendritic compartment of indirect-pathway MSNs. Each protomer would maintain its canonical G protein coupling (G_s for $A_{2A}R$, and G_i for CB_1R). In this study we propose (*middle*) that the $A_{2A}R-CB_1R$ heteromer would facilitate G_q rather than G_s or G_i coupling. In symptomatic HD (*right*), the $A_{2A}R-CB_1R$ heteromer would be disrupted into its constituting protomers.

the action of both agonists was blocked when the slices were preincubated with the partner receptor antagonists, SR141716 or ZM241385, thus showing cross-antagonism (Figure 4b and c). Interestingly, in Hdh^{Q7/Q111} mice this

negative cross-talk and cross-antagonism signature was not detected (Figure 4d and e), in line with the PLA data showing that the $A_{2A}R$ - CB_1R heteromer is indeed not expressed in 6-month-old Hdh^{Q7/Q111} mice. Of note, and also in line with

the data shown above, this loss of cross-signaling did not appear to be simply due to the loss of surface expression of functional receptors, as the extent of single agonist-evoked ERK and Akt stimulation was roughly equivalent in both Hdh^{Q7/Q111} and Hdh^{Q7/Q7} mice (Figure 4b–e).

Together, these data demonstrate that a selective loss of functional $A_{2A}R$ - CB_1R heteromers accompanies disease progression in mouse models of HD.

A_{2A}R-CB₁R Heteromers are Lost in the Caudate-Putamen of High-Grade HD Patients

We next investigated whether the aforementioned changes in A_{2A}R-CB₁R heteromer expression found in HD mouse models are also evident in HD. Thus, we used the PLA technique to analyze human caudate-putamen post mortem samples from control subjects and HD patients at different grades. A2AR-CB1R heteromers were readily evident in the caudate-putamen of control individuals, with a high fraction (~65%) of total cells expressing heteromers (Figure 5a and g, and Supplementary Table S1). These complexes were also detected at those normal levels in asymptomatic huntingtin gene-mutation carriers (HD grade 0) and early symptomatic HD patients (HD grades 1-2) (Figure 5b-d and g, and Supplementary Table S1). In contrast, A_{2A}R-CB₁R heteromers were strongly reduced in caudate-putamen samples from high-grade, advanced HD patients (HD grades 3-4), with only $\sim 10\%$ of total cells containing PLA-positive dots (Figure 5e-g, and Supplementary Table S1). PLA labeling was quite uniform in the caudate-putamen sections analyzed, and thus no perceptible differences in A2AR-CB1R heteromer expression were detected between those two nuclei within each subject (Supplementary Figure S8a and b). In addition, the demographic characteristics of the samples used indicated that the control, low-grade HD and high-grade HD subject populations were rather homogeneous (Supplementary Table S1), thus supporting that the differences found in A2AR-CB1R heteromer expression were not due to those confounding factors. Taken together, these data support that the human brain expresses A_{2A}R-CB₁R heteromers, and suggest that these complexes might serve specific functions that are impaired at late stages of HD progression.

DISCUSSION

Despite the progress made toward identifying and understanding GPCR heteromers, their promise as precision drug targets has yet to be fully realized due to the lack of detailed expression maps and functional profiles. A first important conclusion of our study refers to the precise location of the A2AR-CB1R heteromer in the mouse dorsal striatum. The current view in the field supports that a major site of A_{2A}R and CB₁R colocalization is the corticostriatal-neuron terminal, at which the two receptors could physically interact to form $A_{2A}R$ -CB₁R heteromers (Figure 5h). These presynaptic heteromers have been suggested to provide a frame to explain, at least in part, the negative pharmacological interactions between A_{2A}R and CB₁R that occur in the corticostriatal pathway (Ferre et al, 2010; Tebano et al, 2012; Ferreira et al, 2015; Chiodi et al, 2016). However, those previous studies on $A_{2A}R$ -CB₁R heteromers, although elegant and carefully conducted, lacked state-of-the-art genetic controls and heteromer-detecting techniques. Thus, to evaluate the possible existence of A_{2A}R-CB₁R heteromers in corticostriatal neurons, we have made use of three potent genetic models, namely (i) mice lacking CB_1R selectively in cortical glutamatergic neurons, (ii) CB₁R-deficient mice in which CB₁R expression is selectively rescued in cortical glutamatergic neurons, and (iii) CB₁R-floxed mice in which CB₁R is selectively excised in corticostriatal neurons. Systematic PLA assays conducted in these mouse models strikingly showed that the expression of the A2AR-CB1R heteromer in corticostriatal projections to the dorsal striatum is negligible (Figure 1c). This finding supports that the inhibitory cross-talk processes between A2AR and CB1R reported to date in corticostriatal terminals do not rely primarily on physical interactions between the two receptors at the plasma membrane, but on other potential factors such us an opposite G_s/G_i protein-dependent downstream signaling converging on glutamate release at the presynapse, which, in turn, would conceivably lead to an opposite modulation of the mGluR₅/ phospholipase C- β /diacylglycerol lipase- α (DAGL α)/2-arachidonoylglycerol (2-AG) retrograde-signaling machinery at the postsynapse (Uchigashima et al, 2007; Katona and Freund, 2008). In any case, this observed absence of presynaptic A2AR-CB₁R heteromers does certainly not preclude that A_{2A}R and CB₁R could interact with other partners at corticostriatal terminals to form GPCR complexes, for example, the A1R-A_{2A}R heteromer (Ciruela et al, 2006; Quiroz et al, 2009).

Another widely accepted site at which striatal A_{2A}R-CB₁R heteromers are believed to reside is the somatodendritic compartment of MSNs, the main target of corticostriatal inputs (Carriba et al, 2007; Schiffmann et al, 2007; Ferre et al, 2010) (Figure 5h). Here, by using (i) mice lacking CB₁R selectively in GABAergic neurons, (ii) CB₁R-deficient mice in which CB₁R expression is selectively rescued in GABAergic neurons, (iii) mice lacking CB1R selectively in D1R-expressing MSNs, and (iv) CB₁R-floxed mice in which CB₁R is selectively excised in MSNs, we cogently demonstrated that the A2AR-CB1R heteromer is indeed present in indirect-pathway MSNs (Figure 1 and Supplementary Figure S2). It is well established that CB₁R is largely a presynaptic receptor that is highly abundant in the resident collaterals and long-range projections of MSNs (Uchigashima et al, 2007; Katona and Freund, 2008). Our data support that A2AR-CB1R heteromers are not solely expressed in the somatodendritic compartment of indirectpathway MSNs, but, most likely, also at terminals of these neurons (Figure 5h). Nonetheless, the higher PLA signal found in $GABA-CB_1R^{-/-}$ and $GABA-Glu-CB_1R^{-/-}$ mice compared with full $CB_1R^{-/-}$ mice (Figure 1c and Supplementary Figure S1c) suggests that, in the dorsal striatum, A_{2A}R-CB₁R heteromers may also be located on non-GABAergic, non-glutamatergic cells/terminals such as cholinergic interneurons, dopaminergic projections, or astrocytes. We are also aware that understanding the precise role of A_{2A}R-CB₁R complexes in indirect-pathway MSNs is an extremely complex issue. This complexity is due, in part, to the possibility that A_{2A}R and CB₁R can interact with other receptors in indirect-pathway MSNs. For example, A_{2A}R is highly coexpressed with both D₂R and mGluR₅, which colocalizes with DAGLa at the perisynaptic border of dendritic spines of MSNs (Uchigashima et al, 2007; Katona and Freund, 2008). The activation of mGluR₅ by glutamate spillover derived from corticostriatal overactivity, which leads to DAGLa-mediated

2-AG generation, can be tuned by D_2R in MSN dendritic spines (Kreitzer and Malenka, 2005; Yin and Lovinger, 2006). In addition, $A_{2A}R$ antagonists potentiate 2-AG release and long-term depression in indirect-pathway MSNs (Lerner *et al*, 2010). Whether these intricate interactions between $A_{2A}R$, D_2R and mGluR₅ rely, at least in part, on putative $A_{2A}R$ - D_2R mGluR₅ heteromers (Cabello *et al*, 2009) has still to be defined. To complicate the situation further, postsynaptic $A_{2A}R$ and D_2R might form other higher-order heteromeric complexes, including a proposed $A_{2A}R$ - CB_1R - D_2R heteromer (Navarro *et al*, 2010; Bonaventura *et al*, 2014). This functional conundrum notwithstanding, the present study provides a cogent understanding of the anatomical distribution of the $A_{2A}R$ - CB_1R heteromer, or the complexes containing the heteromer, in the corticostriatal circuit.

Our data also support that the selective coupling to G_a protein, rather than to G_s or G_i proteins, is a biochemical hallmark of the A2AR-CB1R heteromer in striatal cells (Figure 5h). A G protein switch has in fact been suggested to occur in several GPCR heteromerization processes. For example, a change from the archetypical G_s-coupled D₁R (either as monomer or as D1R-D1R homomers) to noncanonical Gi-coupled D1R-HT3R heteromer has been observed (Ferrada et al, 2009). In addition, formation of the CB₁R-5-HT_{2A}R heteromer may lead to a switch in G protein coupling for 5-HT_{2A}R from G_q to G_i protein (Viñals et al, 2015). Thus, it is possible that in a striatopallidal MSN, there is a coexistence of A_{2A}R and CB₁R (as both monomers and A_{2A}R-A_{2A}R and CB₁R-CB₁R homomers), which are widely believed to couple to G_{s/olf} and G_i proteins, respectively, together with $A_{2A}R$ -CB₁R heteromers, which could couple non-canonically to Gq protein. How these processes of GPCR protein-protein interaction and subsequent G protein 'shuffling' affect corticostriatal circuitry is as yet unknown. It is conceivable that the arrangement of the aforementioned heteromers from A2AR and CB1R protomers in striatopallidal MSNs, by recruiting activatory G_q proteins, would be a way to fuel the indirect pathway and therefore blunt motor activity. However, such a functional outcome is difficult to predict as, according to the currently accepted models of basal ganglia function, motor activation relies on the simultaneous and coordinated activation of the direct and indirect striatal pathways (Nelson and Kreitzer, 2014). In any case, our data support the existence of different pools of A_{2A}R and CB₁R with different G protein coupling in corticostriatal projections, striatopallidal MSNs and striatonigral MSNs, thus providing adenosinergic and cannabinergic cross-signaling with an extreme degree of complexity.

To study whether the $A_{2A}R$ -CB₁R heteromer is affected in a pathological setting we selected HD as the archetypal neurodegenerative disease that primarily affects MSNs in a selective manner. A significant number of studies have dealt with CB₁R expression and function in HD. In particular, a downregulation of CB₁R expression has been documented in the caudate-putamen of HD patients and the dorsal striatum of some HD animal models, which seems to reflect the characteristic damage pattern of MSNs (Glass *et al*, 2000; Fernandez-Ruiz *et al*, 2011). In addition, we (Blazquez *et al*, 2011) and others (Mievis *et al*, 2011b) have demonstrated a neuroprotective role of CB₁R in transgenic mouse models of HD. Likewise, administration of the cannabinoid agonist THC to HD mice prevented disease progression as assessed by behavioral, neuropathological, and molecular markers (Blazquez et al, 2011). In sum, it is currently believed that CB_1R may be neuroprotective in HD. Regarding $A_{2A}R$, its expression has been shown to decrease in striatopallidal MSNs from the caudate-putamen of HD patients and the dorsal striatum of some HD animal models (Glass et al, 2000; Lee and Chern, 2014). However, the precise role of A_{2A}R in HD progression is not obvious yet, as conflicting results have been reported. Thus, administration of the A2AR agonist CGS21680 to HD mice prevented neuropathological deficits and improved motor alterations, although it had no effect on body weight or lifespan (Chou et al, 2005). Likewise, the dual-function compound T1-11, which simultaneously activates A2AR and blocks adenosine transport, improved motor coordination deficits, reduced striatal huntingtin aggregates, and normalized proteasomal activity (Huang et al, 2011). Genetic ablation of A_{2A}R in HD mice worsened motor performance, decreased animal survival, and reduced striatal enkephalin expression (Mievis et al, 2011a), and also reversed working memory deficits (Li et al, 2015). However, and in striking contrast, administration of the A2AR antagonist SCH58261 exerted beneficial effects in HD mice by attenuating anxiety-like responses and sensitivity to excitotoxins, although it had no effect on motor coordination (Domenici et al, 2007). Because of these (at least apparently) contradictory data coming from various A2AR gain-of-function and loss-of-function approaches, it is conceivable that A2AR can mediate different (even opposing) molecular and physiopathological mechanisms depending on its cellular location and, hence, its extent of heteromerization. It has been proposed that a selective functional impairment of A2AR located on striatopallidal MSNs occurs at pre-symptomatic stages of HD, whereas presynaptic A_{2A}R function is not affected (Orru et al, 2011). Of note, CB₁R is also lost in MSNs but not in corticostriatal projections along HD progression (Chiodi et al, 2012; Chiarlone et al, 2014). This suggests that the corticostriatal pool of non-heteromerizing A_{2A}R and CB₁R would be the main target of adenosinergic and cannabinergic drugs aimed at relieving the symptoms of HD at late stages, whereas the MSN pool of A2AR-CB1R heteromers could be an additional target of those drugs at early disease stages. As A2AR-CB1R heteromers are lost in the caudateputamen of high-grade HD patients, the heteromer's specific functions would be impaired at advanced stages of HD progression. Thus, the fine negative cross-talk between adenosine and endocannabinoids would conceivably disappear in advanced HD, and one might speculate that the G_q specific signaling would be lost as well at those late disease stages (Figure 5h). The $A_{2A}R$ -CB₁R heteromer is singular in both its specific localization on indirect-pathway MSNs and its biochemical characteristics owing to its coupling to noncanonical G_q-mediated signaling. Together, our findings may open a new conceptual framework to understand the role of coordinated adenosine-cannabinoid function in the indirect striatal pathway, which may be relevant in motor function and neural diseases.

FUNDING AND DISCLOSURE

This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO/FEDER; grant SAF2015-64945-R to MG; grant SAF-2014-54840-R to EIC and VC; grant SAF2015-65034-R to PG; grant SAF2015-67474-R to SG; grants SAF2014-55700-P and PCIN-2013-019-C03-03 to FC); Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED; grant PI2013/05 to MG, PJM and EIC); Comunidad de Madrid (grant S2010/BMD-2308 to MG); Generalitat de Catalunya (grant 2014-SGR-1236 to EIC); 'La Marató de TV3' Foundation (grant 20140610 to EIC; grant 20152031 to FC); Agentschap voor Innovatie door Wetenschap en Technologie (grant SBO-140028 to FC); BBSRC DTP studentship (to PJM and LB); EPSRC (grant EP/M006379/1 to LAH); Deutsche Forschungsgemeinschaft (DFG; grant MO 1920/1-1 to KM; grant CRC-TRR 58 to BL); Institute of Health Carlos III from the Spanish Ministry of Economy and Competitiveness (grant PIE14/00034 to FC; grant PI10/00172 and funding from FEDER grants to MJC and JP); The Basque Government (grant IT764-13 to PG); University of the Basque Country UPV/EHU (grant UFI11/41 to PG); Red de Trastornos Adictivos-Institute of Health Carlos III (grant RD12/0028/ 0004 to PG). AC is supported by the Spanish Ministry of Economy and Competitiveness (Juan de la Cierva Program). MM is supported by the Spanish Ministry of Education, Culture and Sport (FPU Program). The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We are very grateful to Cristina Blázquez, Manel Bosch, Elena García-Taboada, Ana Gómez, Bernadette Mohr, María P Muñoz, and Alicia Poplawski for their expert technical assistance.

REFERENCES

- Araki KY, Fujimura S, MacDonald ME, Bhide PG (2006). Characterization of mouse striatal precursor cell lines expressing functional dopamine receptors. *Dev Neurosci* 28: 518–527.
- Azdad K, Gall D, Woods AS, Ledent C, Ferre S, Schiffmann SN (2009). Dopamine D2 and adenosine A2A receptors regulate NMDAmediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. *Neuropsychopharmacology* 34: 972–986.
- Bellocchio L, Lafenetre P, Cannich A, Cota D, Puente N, Grandes P *et al* (2010). Bimodal control of stimulated food intake by the endocannabinoid system. *Nat Neurosci* **13**: 281–283.
- Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E *et al* (2011). Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. *Brain* **134**: 119–136.
- Bonaventura J, Navarro G, Casado-Anguera V, Azdad K, Rea W, Moreno E *et al* (2015). Allosteric interactions between agonists and antagonists within the adenosine A_{2A} receptor-dopamine D_2 receptor heterotetramer. *Proc Natl Acad Sci USA* **112**: E3609–E3618.
- Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, Luquin N et al (2014). L-DOPA-treatment in primates disrupts the expression of A_{2A} adenosine-CB₁ cannabinoid-D₂ dopamine receptor heteromers in the caudate nucleus. *Neuropharmacology* **79**: 90–100.
- Cabello N, Gandia J, Bertarelli DC, Watanabe M, Lluis C, Franco R et al (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem **109**: 1497–1507.
- Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A *et al* (2007). Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology* **32**: 2249–2259.

- Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012). Endocannabinoid signaling and synaptic function. *Neuron* **76**: 70–81.
- Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M *et al* (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. *J Neurosci* **26**: 2080–2087.
- Chiarlone A, Bellocchio L, Blazquez C, Resel E, Soria-Gomez E, Cannich A *et al* (2014). A restricted population of CB1 cannabinoid receptors with neuroprotective activity. *Proc Natl Acad Sci USA* **111**: 8257–8262.
- Chiodi V, Ferrante A, Ferraro L, Potenza RL, Armida M, Beggiato S *et al* (2016). Striatal adenosine-cannabinoid receptor interactions in rats overexpressing adenosine A₂ receptors. *J Neurochem* **136**: 907–917.
- Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A *et al* (2012). Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. *Neurobiol Dis* **45**: 983–991.
- Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH *et al* (2005). CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. *J Neurochem* **93**: 310–320.
- De Salas-Quiroga A, Diaz-Alonso J, Garcia-Rincon D, Remmers F, Vega D, Gomez-Canas M *et al* (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB₁ receptors on developing cortical neurons. *Proc Natl Acad Sci USA* **112**: 13693–13698.
- Denovan-Wright EM, Robertson HA (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. *Neuroscience* **98**: 705–713.
- Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A *et al* (2007). Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. *Neurobiol Dis* **28**: 197–205.
- Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S *et al* (2011). Prospects for cannabinoid therapies in basal ganglia disorders. *Br J Pharmacol* **163**: 1365–1378.
- Ferrada C, Moreno E, Casado V, Bongers G, Cortes A, Mallol J *et al* (2009). Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. *Br J Pharmacol* **157**: 64–75.
- Ferre S, Lluis C, Justinova Z, Quiroz C, Orru M, Navarro G *et al* (2010). Adenosine-cannabinoid receptor interactions. Implications for striatal function. *Br J Pharmacol* **160**: 443–453.
- Ferreira SG, Goncalves FQ, Marques JM, Tome AR, Rodrigues RJ, Nunes-Correia I *et al* (2015). Presynaptic adenosine A_{2A} receptors dampen cannabinoid CB₁ receptor-mediated inhibition of corticostriatal glutamatergic transmission. *Br J Pharmacol* **172**: 1074–1086.
- Girault JA (2012). Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol **970**: 407-429.
- Glass M, Dragunow M, Faull RL (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and $GABA_A$ receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* **97**: 505–519.
- Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sanchez-Soto M *et al* (2014). Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D₁-D₃ receptor heterotetramer. *Mol Pharmacol* **86**: 417–429.
- He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB et al (2011). Facilitation of mu-opioid receptor activity by preventing deltaopioid receptor-mediated codegradation. Neuron 69: 120–131.
- Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y *et al* (2016). Crystal structure of the human cannabinoid receptor CB₁. *Cell* **167**: 750–762.
- Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ et al (2011). A new drug design targeting the adenosinergic system for Huntington's disease. *PLoS One* **6**: e20934.

- Justinova Z, Redhi GH, Goldberg SR, Ferre S (2014). Differential effects of presynaptic versus postsynaptic adenosine A_{2A} receptor blockade on delta-9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. *J Neurosci* **34**: 6480–6484.
- Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. *Nat Med* **14**: 923–930.
- Kreitzer AC (2009). Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 32: 127–147.
- Kreitzer AC, Malenka RC (2005). Dopamine modulation of statedependent endocannabinoid release and long-term depression in the striatum. *J Neurosci* **25**: 10537–10545.
- Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ *et al* (1997). Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. *Nature* **388**: 674–678.
- Lee CF, Chern Y (2014). Adenosine receptors and Huntington's disease. *Int Rev Neurobiol* 119: 195–232.
- Lee LT, Ng SY, Chu JY, Sekar R, Harikumar KG, Miller LJ *et al* (2014). Transmembrane peptides as unique tools to demonstrate the *in vivo* action of a cross-class GPCR heterocomplex. *FASEB J* 28: 2632–2644.
- Lerner TN, Horne EA, Stella N, Kreitzer AC (2010). Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. *J Neurosci* **30**: 2160–2164.
- Li W, Silva HB, Real J, Wang YM, Rial D, Li P *et al* (2015). Inactivation of adenosine A_{2A} receptors reverses working memory deficits at early stages of Huntington's disease models. *Neurobiol Dis* **79**: 70–80.
- Lovinger DM (2010). Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. *Neuropharmacology* **58**: 951–961.
- Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG *et al* (2002). The endogenous cannabinoid system controls extinction of aversive memories. *Nature* **418**: 530–534.
- McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM (2004). Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. *Eur J Biochem* 271: 4909–4920.
- Mievis S, Blum D, Ledent C (2011a). A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. *Neurobiol Dis* **41**: 570–576.
- Mievis S, Blum D, Ledent C (2011b). Worsening of Huntington disease phenotype in CB1 receptor knockout mice. *Neurobiol Dis* 42: 524–529.
- Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schutz G *et al* (2007). Genetic dissection of behavioural and autonomic effects of delta-9-tetrahydrocannabinol in mice. *PLoS Biol* 5: e269.
- Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R *et al* (2006). The endocannabinoid system controls key epilept-ogenic circuits in the hippocampus. *Neuron* **51**: 455–466.
- Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A et al (2008). Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8: 1088–1097.
- Navarro G, Ferre S, Cordomi A, Moreno E, Mallol J, Casado V *et al* (2010). Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. *J Biol Chem* **285**: 27346–27359.
- Nelson AB, Kreitzer AC (2014). Reassessing models of basal ganglia function and dysfunction. *Annu Rev Neurosci* **37**: 117–135.
- Orru M, Zanoveli JM, Quiroz C, Nguyen HP, Guitart X, Ferre S (2011). Functional changes in postsynaptic adenosine A_{2A} receptors during early stages of a rat model of Huntington disease. *Exp Neurol* **232**: 76–80.

- Quiroz C, Lujan R, Uchigashima M, Simoes AP, Lerner TN, Borycz J *et al* (2009). Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. *ScientificWorldJournal* **9**: 1321–1344.
- Ruehle S, Remmers F, Romo-Parra H, Massa F, Wickert M, Wortge S *et al* (2013). Cannabinoid CB_1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. *J Neurosci* **33**: 10264–10277.
- Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S (2007). Adenosine A2A receptors and basal ganglia physiology. *Prog Neurobiol* 83: 277–292.
- Schiffmann SN, Vanderhaeghen JJ (1993). Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13: 1080–1087.
- Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999). *In vivo* protein transduction: delivery of a biologically active protein into the mouse. *Science* 285: 1569–1572.
- Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J et al (2016). High-resolution crystal structure of the human CB1 cannabinoid receptor. *Nature* [Epub ahead of print].
- Shoichet BK, Kobilka BK (2012). Structure-based drug screening for G-protein-coupled receptors. *Trends Pharmacol Sci* 33: 268–272.
- Taura J, Fernandez-Duenas V, Ciruela F (2015). Visualizing G proteincoupled receptor-receptor interactions in brain using proximity ligation in situ assay. *Curr Protoc Cell Biol* **67**: 17 17 11–16.
- Tebano MT, Martire A, Popoli P (2012). Adenosine A_{2A} -cannabinoid CB₁ receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission. *Brain Res* **1476**: 108–118.
- Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F et al (2000). Dominant phenotypes produced by the HD mutation in STHdh^{Q111} striatal cells. Hum Mol Genet 9: 2799–2809.
- Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007). Subcellular arrangement of molecules for 2arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. *J Neurosci* **27**: 3663–3676.
- Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM (2013). Molecular signatures of G-protein-coupled receptors. *Nature* 494: 185–194.
- Viñals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de La Torre R et al (2015). Cognitive impairment induced by delta-9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB₁ and serotonin 5-HT_{2A} receptors. *PLoS Biol* **13**: e1002194.
- Walker FO (2007). Huntington's disease. Lancet 369: 218-228.
- Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG *et al* (2011). Structure of an agonist-bound human A2A adenosine receptor. *Science* **332**: 322–327.
- Yin HH, Lovinger DM (2006). Frequency-specific and D2 receptormediated inhibition of glutamate release by retrograde endocannabinoid signaling. *Proc Natl Acad Sci USA* 103: 8251–8256.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/

© The Author(s) 2018

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)